Role of microRNA-21 and microRNA-155 as biomarkers for bronchial asthma

ElKashef, Sabrin Mohamed Mohamed Abd Elhamed; Ahmad, Sohair El-Attar; Soliman, Youssef; Mostafa, Mohammed

doi:10.1177/1753425920901563

Cited by 27 publications

(35 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Elkashef et al. have reported the use of miR-21 and miR-155 as biomarkers in bronchial asthma ( 62 ). They showed that both miRNAs are higher in serum of individuals with eosinophilic asthma than healthy subjects.…”

Section: Mirnas In Lung Diseasesmentioning

confidence: 99%

MicroRNAs as Potential Regulators of Immune Response Networks in Asthma and Chronic Obstructive Pulmonary Disease

et al. 2021

View full text Add to dashboard Cite

Chronic respiratory diseases (CRDs) are an important factor of morbidity and mortality, accounting for approximately 6% of total deaths worldwide. The main CRDs are asthma and chronic obstructive pulmonary disease (COPD). These complex diseases have different triggers including allergens, pollutants, tobacco smoke, and other risk factors. It is important to highlight that although CRDs are incurable, various forms of treatment improve shortness of breath and quality of life. The search for tools that can ensure accurate diagnosis and treatment is crucial. MicroRNAs (miRNAs) are small non-coding RNAs and have been described as promising diagnostic and therapeutic biomarkers for CRDs. They are implicated in multiple processes of asthma and COPD, regulating pathways associated with inflammation, thereby showing that miRNAs are critical regulators of the immune response. Indeed, miRNAs have been found to be deregulated in several biofluids (sputum, bronchoalveolar lavage, and serum) and in both structural lung and immune cells of patients in comparison to healthy subjects, showing their potential role as biomarkers. Also, miRNAs play a part in the development or termination of histopathological changes and comorbidities, revealing the complexity of miRNA regulation and opening up new treatment possibilities. Finally, miRNAs have been proposed as prognostic tools in response to both conventional and biologic treatments for asthma or COPD, and miRNA-based treatment has emerged as a potential approach for clinical intervention in these respiratory diseases; however, this field is still in development. The present review applies a systems biology approach to the understanding of miRNA regulatory networks in asthma and COPD, summarizing their roles in pathophysiology, diagnosis, and treatment.

show abstract

Section: Mirnas In Lung Diseasesmentioning

confidence: 99%

MicroRNAs as Potential Regulators of Immune Response Networks in Asthma and Chronic Obstructive Pulmonary Disease

et al. 2021

View full text Add to dashboard Cite

show abstract

“…According to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) standard, 47 the standard literature selection process was conducted as shown in Figure 1 . We finally included 72 articles 21 , 22 , 25 – 31 , 48 …”

Section: Resultsmentioning

confidence: 99%

“…In particular, there were five publications 51 , 53 , 55 , 61 , 92 among the 72 articles with the data details required for quantitative diagnosis analysis for miRNAs in asthma ( Table 2 ). There is no threshold effect based on the analysis of Spearman (Spearman correlation = 0.5946) which means that the study effect size could be combined.…”

Section: Resultsmentioning

confidence: 99%

“… 61 Similar situations of samples derived from different regions or different cut-off also affect the results of miR-21 for asthma. 26 , 27 , 51 , 92 These indicate that further research could be optimized from the above aspects to increase the homogeneity.…”

Section: Discussionmentioning

confidence: 98%

“…For instance, the expression level for miR-155 could go in a different direction when compared with different control groups. 49 , 72 Moreover, depending on the cut-off of expression value of miRNAs, the Sen and Spe for miR-155 could be as high as 100% 51 or go down to 80% and 89%, respectively. 61 Similar situations of samples derived from different regions or different cut-off also affect the results of miR-21 for asthma.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

A comprehensive analysis of microRNAs as diagnostic biomarkers for asthma

Tan

et al. 2020

Ther Adv Respir Dis

View full text Add to dashboard Cite

Background: It is unclear whether microRNAs could be a potential diagnostic biomarker for asthma or not. The objective of this study is to figure out the diagnostic value of microRNAs in asthma. Methods: Literature retrieval, screening of publications, specific data extraction, and quality evaluation were conducted according to the standard criteria. Stata 14.0 software was used to analyze the diagnostic value of microRNA for asthma, including the combined sensitivity (Sen), specificity (Spe), the area under the curve (AUC), positive likelihood ratio (PLR), negative likelihood ratio (NLR), and diagnostic odds ratio (DOR). Results: A total of 72 studies, containing 4143 cases and 2188 controls, were included for this comprehensive analysis. None of the included publications were rated low in quality. We summarized that, compared with controls, more than 100 miRNAs were reported differently expressed in asthma, although the expression trends were inconsistent. Besides, there were five studies among these 72 articles that applied the diagnostic evaluation of microRNAs in asthma. We found that the pooled Sen, Spe, and AUC for the combination of miR-185-5p, miR-155, let-7a, miR-21, miR-320a, miR-1246, miR-144-5p, and miR-1165-3p in asthma were 0.87 (95%CI: 0.72–0.95), 0.84 (95%CI: 0.74–0.91), and 0.93 (95%CI: 0.89–0.94) individually, and the PLR, NLR, and DOR were 5.5 (95%CI: 3.1–9.7), 0.15 (95%CI: 0.07–0.36), and 35 (95%CI: 10–127) in asthma, respectively. In terms of subgroup analyses, we found that the Sen for these combination miRNAs from serum was higher than that in plasma, while the Spe in plasma worked better than that in serum. Furthermore, compared with children, the combination of above miRNAs from adults had higher Spe and similar Sen. Conclusions: From our analysis, the combination of miR-185-5p, miR-155, let-7a, miR-21, miR-320a, miR-1246, miR-144-5p, and miR-1165-3p from peripheral blood could potentially act as a diagnostic biomarker for asthma. The reviews of this paper are available via the supplemental material section.

show abstract

Exosomes in asthma: Underappreciated contributors to the pathogenesis and novel therapeutic tools

Kanannejad,

Arab,

Soleimanian

et al. 2024

Immunity Inflam & Disease

View full text Add to dashboard Cite

ObjectiveAsthma, a chronic inflammatory disease with diverse pathomechanisms, presents challenges in developing personalized diagnostic and therapeutic approaches. This review aims to provide a comprehensive overview of the role of exosomes, small extracellular vesicles, in asthma pathophysiology and explores their potential as diagnostic biomarkers and therapeutic tools.MethodsA literature search was conducted to identify recent studies investigating the involvement of exosomes in asthma. The retrieved articles were analyzed to extract relevant information on the role of exosomes in maintaining lung microenvironment homeostasis, regulating inflammatory responses, and their diagnostic and therapeutic potential for asthma.ResultsExosomes secreted by various cell types, have emerged as crucial mediators of intercellular communication in healthy and diseased conditions. Evidence suggest that exosomes play a significant role in maintaining lung microenvironment homeostasis and contribute to asthma pathogenesis by regulating inflammatory responses. Differential exosomal content between healthy individuals and asthmatics holds promise for the development of novel asthma biomarkers. Furthermore, exosomes secreted by immune and nonimmune cells, as well as those detected in biofluids, demonstrate potential in promoting or regulating immune responses, making them attractive candidates for designing new treatment strategies for inflammatory conditions such as asthma.ConclusionExosomes, with their ability to modulate immune responses and deliver therapeutic cargo, offer potential as targeted therapeutic tools in asthma management. Further research and clinical trials are required to fully understand the mechanisms underlying exosome‐mediated effects and translate these findings into effective diagnostic and therapeutic strategies for asthma patients.

show abstract

Role of microRNA-21 and microRNA-155 as biomarkers for bronchial asthma

Cited by 27 publications

References 45 publications

MicroRNAs as Potential Regulators of Immune Response Networks in Asthma and Chronic Obstructive Pulmonary Disease

MicroRNAs as Potential Regulators of Immune Response Networks in Asthma and Chronic Obstructive Pulmonary Disease

A comprehensive analysis of microRNAs as diagnostic biomarkers for asthma

Exosomes in asthma: Underappreciated contributors to the pathogenesis and novel therapeutic tools

Contact Info

Product

Resources

About